Online inquiry

IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13464MR)

This product GTTS-WQ13464MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ERBB2&TNFRSF9 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001005862.3; NM_001561.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064; 3604
UniProt ID P04626; Q07011
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ13464MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12497MR IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA NOE-102
GTTS-WQ8190MR IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA HL161
GTTS-WQ132MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ1273MR IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-414
GTTS-WQ13996MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ13774MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-1033
GTTS-WQ13556MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PRX-302
GTTS-WQ13299MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-06523435
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW